Les facteurs incluent le sexe féminin, des antécédents familiaux et d'autres maladies auto-immunes.
Facteurs de risqueMaladies auto-immunesLupus érythémateux
#2
L'âge influence-t-il le risque ?
Oui, le risque est plus élevé chez les jeunes femmes, généralement entre 15 et 45 ans.
ÂgeRisqueLupus érythémateux
#3
Les antécédents médicaux jouent-ils un rôle ?
Oui, des antécédents de maladies auto-immunes augmentent le risque d'inhibiteur lupique.
Antécédents médicauxMaladies auto-immunesRisque
#4
Le stress peut-il être un facteur de risque ?
Oui, le stress peut exacerber les symptômes et augmenter le risque de complications.
StressRisqueComplications
#5
Y a-t-il des facteurs environnementaux ?
Oui, l'exposition à certains médicaments ou à des agents environnementaux peut être un facteur.
EnvironnementMédicamentsFacteurs de risque
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Inhibiteur lupique de la coagulation : Questions médicales les plus fréquentes",
"headline": "Inhibiteur lupique de la coagulation : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Inhibiteur lupique de la coagulation : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-16",
"dateModified": "2025-04-11",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Inhibiteur lupique de la coagulation"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Inhibiteurs des facteurs de la coagulation sanguine",
"url": "https://questionsmedicales.fr/mesh/D019774",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs des facteurs de la coagulation sanguine",
"code": {
"@type": "MedicalCode",
"code": "D019774",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.113"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteur lupique de la coagulation",
"alternateName": "Lupus Coagulation Inhibitor",
"code": {
"@type": "MedicalCode",
"code": "D016682",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Thomas Schmitz",
"url": "https://questionsmedicales.fr/author/Thomas%20Schmitz",
"affiliation": {
"@type": "Organization",
"name": "Pharmaceutical Biochemistry and Bioanalytics, Pharmaceutical Institute, University of Bonn, An der Immenburg 4, D-53121, Bonn, Germany."
}
},
{
"@type": "Person",
"name": "Charlotte A Bäuml",
"url": "https://questionsmedicales.fr/author/Charlotte%20A%20B%C3%A4uml",
"affiliation": {
"@type": "Organization",
"name": "Pharmaceutical Biochemistry and Bioanalytics, Pharmaceutical Institute, University of Bonn, An der Immenburg 4, D-53121, Bonn, Germany."
}
},
{
"@type": "Person",
"name": "Diana Imhof",
"url": "https://questionsmedicales.fr/author/Diana%20Imhof",
"affiliation": {
"@type": "Organization",
"name": "Pharmaceutical Biochemistry and Bioanalytics, Pharmaceutical Institute, University of Bonn, An der Immenburg 4, D-53121, Bonn, Germany. Electronic address: dimhof@uni-bonn.de."
}
},
{
"@type": "Person",
"name": "Jeremy W Jacobs",
"url": "https://questionsmedicales.fr/author/Jeremy%20W%20Jacobs",
"affiliation": {
"@type": "Organization",
"name": "Department of Laboratory Medicine, Yale School of Medicine, 330 Cedar Street, New Haven, CT, 06520, USA. Jeremy.jacobs@yale.edu."
}
},
{
"@type": "Person",
"name": "Jiraphorn Issara-Amphorn",
"url": "https://questionsmedicales.fr/author/Jiraphorn%20Issara-Amphorn",
"affiliation": {
"@type": "Organization",
"name": "Medical Microbiology, Interdisciplinary and International Program, Graduate School, Chulalongkorn University, Bangkok, Thailand."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Isolated Prolongation of Activated Partial Thromboplastin Time: Not Just Bleeding Risk!",
"datePublished": "2023-06-17",
"url": "https://questionsmedicales.fr/article/37374373",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/medicina59061169"
}
},
{
"@type": "ScholarlyArticle",
"name": "Comparative analysis on characteristics of two activated partial thromboplastin time reagents.",
"datePublished": "2022-07-19",
"url": "https://questionsmedicales.fr/article/35853032",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/jcla.24608"
}
},
{
"@type": "ScholarlyArticle",
"name": "Activated Partial Thromboplastin Time and Prothrombin Time Mixing Studies: Current State of the Art.",
"datePublished": "2022-09-02",
"url": "https://questionsmedicales.fr/article/36055261",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1055/s-0042-1756196"
}
},
{
"@type": "ScholarlyArticle",
"name": "Genetic Polymorphisms Associated with Prothrombin Time and Activated Partial Thromboplastin Time in Chinese Healthy Population.",
"datePublished": "2022-10-15",
"url": "https://questionsmedicales.fr/article/36292752",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/genes13101867"
}
},
{
"@type": "ScholarlyArticle",
"name": "Activated Partial Thromboplastin Time and Mortality in Coronary Artery Bypass Grafting Patients.",
"datePublished": "2022-09-17",
"url": "https://questionsmedicales.fr/article/36168325",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1155/2022/2918654"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Facteurs biologiques",
"item": "https://questionsmedicales.fr/mesh/D001685"
},
{
"@type": "ListItem",
"position": 3,
"name": "Inhibiteurs des facteurs de la coagulation sanguine",
"item": "https://questionsmedicales.fr/mesh/D019774"
},
{
"@type": "ListItem",
"position": 4,
"name": "Inhibiteur lupique de la coagulation",
"item": "https://questionsmedicales.fr/mesh/D016682"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Inhibiteur lupique de la coagulation - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Inhibiteur lupique de la coagulation",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-04-29",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Inhibiteur lupique de la coagulation",
"description": "Comment diagnostiquer un inhibiteur lupique de la coagulation ?\nQuels tests sont utilisés pour le diagnostic ?\nQuels sont les signes cliniques associés ?\nLe diagnostic nécessite-t-il des antécédents médicaux ?\nPeut-on avoir un inhibiteur sans lupus ?",
"url": "https://questionsmedicales.fr/mesh/D016682?mesh_terms=Partial+Thromboplastin+Time#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Inhibiteur lupique de la coagulation",
"description": "Quels sont les symptômes courants ?\nLes symptômes varient-ils d'une personne à l'autre ?\nY a-t-il des symptômes spécifiques aux femmes ?\nLes symptômes peuvent-ils s'aggraver avec le temps ?\nPeut-on avoir des symptômes sans saignement ?",
"url": "https://questionsmedicales.fr/mesh/D016682?mesh_terms=Partial+Thromboplastin+Time#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Inhibiteur lupique de la coagulation",
"description": "Peut-on prévenir l'inhibiteur lupique ?\nQuels conseils de mode de vie peuvent aider ?\nLes femmes enceintes doivent-elles être surveillées ?\nY a-t-il des vaccinations recommandées ?\nComment gérer le stress pour prévenir les symptômes ?",
"url": "https://questionsmedicales.fr/mesh/D016682?mesh_terms=Partial+Thromboplastin+Time#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Inhibiteur lupique de la coagulation",
"description": "Quels traitements sont disponibles ?\nLes anticoagulants sont-ils toujours nécessaires ?\nY a-t-il des effets secondaires aux traitements ?\nLe traitement est-il à vie ?\nLes traitements sont-ils efficaces ?",
"url": "https://questionsmedicales.fr/mesh/D016682?mesh_terms=Partial+Thromboplastin+Time#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Inhibiteur lupique de la coagulation",
"description": "Quelles sont les complications possibles ?\nLes complications sont-elles fréquentes ?\nComment prévenir les complications ?\nLes complications peuvent-elles être graves ?\nY a-t-il des signes d'alerte pour les complications ?",
"url": "https://questionsmedicales.fr/mesh/D016682?mesh_terms=Partial+Thromboplastin+Time#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Inhibiteur lupique de la coagulation",
"description": "Quels sont les principaux facteurs de risque ?\nL'âge influence-t-il le risque ?\nLes antécédents médicaux jouent-ils un rôle ?\nLe stress peut-il être un facteur de risque ?\nY a-t-il des facteurs environnementaux ?",
"url": "https://questionsmedicales.fr/mesh/D016682?mesh_terms=Partial+Thromboplastin+Time#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer un inhibiteur lupique de la coagulation ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic se fait par des tests de coagulation et la détection d'anticorps spécifiques."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour le diagnostic ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests de temps de céphaline activée (TCA) et les tests d'anticorps anti-cardiolipine sont courants."
}
},
{
"@type": "Question",
"name": "Quels sont les signes cliniques associés ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent des saignements anormaux et des thromboses, souvent sans cause apparente."
}
},
{
"@type": "Question",
"name": "Le diagnostic nécessite-t-il des antécédents médicaux ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les antécédents de lupus ou d'autres maladies auto-immunes sont importants."
}
},
{
"@type": "Question",
"name": "Peut-on avoir un inhibiteur sans lupus ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il est possible d'avoir un inhibiteur lupique sans diagnostic de lupus, bien que rare."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des saignements, des ecchymoses, et des douleurs thoraciques."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils d'une personne à l'autre ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'intensité et la nature des symptômes peuvent varier considérablement entre les individus."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques aux femmes ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les femmes peuvent éprouver des symptômes liés à la grossesse, comme des complications thromboemboliques."
}
},
{
"@type": "Question",
"name": "Les symptômes peuvent-ils s'aggraver avec le temps ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent s'aggraver, surtout sans traitement approprié."
}
},
{
"@type": "Question",
"name": "Peut-on avoir des symptômes sans saignement ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains patients peuvent présenter des symptômes thromboemboliques sans saignement."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir l'inhibiteur lupique ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de méthode de prévention spécifique, mais un suivi médical régulier est conseillé."
}
},
{
"@type": "Question",
"name": "Quels conseils de mode de vie peuvent aider ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain, incluant une alimentation équilibrée et de l'exercice, peut aider."
}
},
{
"@type": "Question",
"name": "Les femmes enceintes doivent-elles être surveillées ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une surveillance étroite est nécessaire pour prévenir les complications pendant la grossesse."
}
},
{
"@type": "Question",
"name": "Y a-t-il des vaccinations recommandées ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les vaccinations doivent être discutées avec un médecin, surtout pour les immunodéprimés."
}
},
{
"@type": "Question",
"name": "Comment gérer le stress pour prévenir les symptômes ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des techniques de gestion du stress, comme la méditation, peuvent aider à réduire les symptômes."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des anticoagulants et des immunosuppresseurs pour gérer les symptômes."
}
},
{
"@type": "Question",
"name": "Les anticoagulants sont-ils toujours nécessaires ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Pas toujours, leur nécessité dépend de la gravité des symptômes et des antécédents médicaux."
}
},
{
"@type": "Question",
"name": "Y a-t-il des effets secondaires aux traitements ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements peuvent avoir des effets secondaires, comme des saignements ou des infections."
}
},
{
"@type": "Question",
"name": "Le traitement est-il à vie ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Cela dépend de la réponse au traitement et de l'évolution de la maladie, souvent à long terme."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils efficaces ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "La plupart des traitements sont efficaces pour contrôler les symptômes et prévenir les complications."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des thromboses, des AVC et des problèmes cardiaques."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles fréquentes ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications peuvent survenir, mais leur fréquence dépend de la gestion de la maladie."
}
},
{
"@type": "Question",
"name": "Comment prévenir les complications ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un traitement approprié et un suivi régulier peuvent aider à prévenir les complications."
}
},
{
"@type": "Question",
"name": "Les complications peuvent-elles être graves ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines complications peuvent être graves et nécessiter une intervention médicale urgente."
}
},
{
"@type": "Question",
"name": "Y a-t-il des signes d'alerte pour les complications ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme des douleurs thoraciques ou des troubles neurologiques doivent alerter immédiatement."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent le sexe féminin, des antécédents familiaux et d'autres maladies auto-immunes."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque est plus élevé chez les jeunes femmes, généralement entre 15 et 45 ans."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux jouent-ils un rôle ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents de maladies auto-immunes augmentent le risque d'inhibiteur lupique."
}
},
{
"@type": "Question",
"name": "Le stress peut-il être un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress peut exacerber les symptômes et augmenter le risque de complications."
}
},
{
"@type": "Question",
"name": "Y a-t-il des facteurs environnementaux ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à certains médicaments ou à des agents environnementaux peut être un facteur."
}
}
]
}
]
}
Pharmaceutical Biochemistry and Bioanalytics, Pharmaceutical Institute, University of Bonn, An der Immenburg 4, D-53121, Bonn, Germany. Electronic address: dimhof@uni-bonn.de.
Publications dans "Inhibiteur lupique de la coagulation" :
Translational Research in Inflammation and Immunology Research Unit (TRIRU), Department of Microbiology, Chulalongkorn University, Bangkok, Thailand, aleelahavanit@gmail.com.
Publications dans "Inhibiteur lupique de la coagulation" :
Department of Pathology and Laboratory Medicine , University of North Carolina at Chapel Hill , 819 Brinkhous-Bullitt Building , Chapel Hill , North Carolina 27599 , United States.
Publications dans "Inhibiteur lupique de la coagulation" :
Activated partial thromboplastin time (aPTT) is a fundamental screening test for coagulation disturbances. An increased aPTT ratio is quite common in clinical practice. How the detection of prolonged ...
For the lack of standardized activated partial thromboplastin time (APTT), it has been pointed out that there are differences in values among several reagents. Recently, we have performed a parallel m...
In order to clarify the factors related to ΔAPTT, multiple regression analysis was performed on 8324 samples, using clinical laboratory data of all test items requested simultaneously with APTT. To co...
Multiple regression analysis detected albumin-globulin ratio (AGR), C-reactive protein (CRP), hematocrit, and prothrombin time as factors related to ΔAPTT (p < 0.001). Results revealed no significant ...
It is considered that the pseudo-prolongation of APTT is triggered by the interaction of CRP on the phospholipid in Coagpia APTT-n, which contributed to the APTT dissociation....
Mixing studies have long been in the clinical laboratory armamentarium for investigating unexpected, prolonged activated partial thromboplastin time (aPTT) or prothrombin time (PT). The purpose of the...
(1) Background: The purpose of this study was to evaluate the effect of gene polymorphisms on prothrombin time (PT) and activated partial thromboplastin time (APTT) in a healthy Chinese population. (2...
To evaluate the prognostic value of preoperative activated partial thromboplastin time (APTT) in patients who underwent coronary artery bypass grafting (CABG)....
All data were extracted from the Medical Information Mart for Intensive Care III (MIMIC-III) database. The study population was divided to two groups according to the optimal cut-off value of APTT cal...
A total of 2,706 patients were included. The optimal cut-off value of APTT for 4-year mortality was 44 seconds. The Cox proportional hazard model showed that patients with APTT ≥ 44 had a significantl...
A longer APTT (≥44) was associated with a higher risk of mortality and can serve as a prognostic predictor in CABG patients....
The aim of this study was to explore the difference in activated partial thromboplastin time (APTT) levels in patients with tuberculous and non-tuberculous pleural effusion (TPE and non-TPE) and its p...
A total of 61 patients diagnosed with tuberculous pleurisy with pleural effusion at Shunde Hospital of Southern Medical University from July 2013 to September 2020 were selected as the observation gro...
The levels of APTT and ADA in the TPE group were significantly higher than the control group, and were 40.03 (37.00, 42.60) (s) and 55.00 (47.00, 69.25) (U/L) for TPE, 29.50 (25.45, 34.20) (s) and 11....
The level of plasma APTT has certain significance in differentiating tuberculous pleural effusion from nontuberculous pleural effusion....
Preeclampsia (PE), an obstetric disorder, remains one of the leading causes of maternal and infant mortality worldwide. In individuals with PE, the coagulation-fibrinolytic system is believed to be am...
This systematic review and meta-analysis was conducted in accordance with the PRISMA guidelines. Articles relevant to the study, published from July 26, 2013, to July 26, 2023, were systematically sea...
A total of 30 articles, involving 5,964 individuals (2,883 with PE and 3,081 as normotensive pregnant mothers), were included in this study. The overall pooled SMD for PT, APTT, and TT between PE and ...
The meta-analysis underscores the association between PE and prolonged PT and APTT. This suggests that evaluating coagulation parameters like PT, APTT, and TT in pregnant women could offer easily acce...
The clot waveform analysis (CWA) provide valuable information beyond clotting time. The present study was planned to assess whether the activated partial thromboplastin time (aPTT)-CWA can differentia...
The aPTT-CWA was generated by an optical detection system (ACL-TOP™ 500 coagulation analyzer) and the other tests were performed as per instructions from the manufacturer in the kit....
A total of 75 samples (47-HA, 16-HAWI, and 12-HB) with prolonged aPTT were recruited. On analyzing the quantitative aPTT-CWA data of HA (non-inhibitors) and HB samples, the width of acceleration 1 [+]...
The aPTT-CWA parameters may be supportive for the differentiation of hemophilia including its severity and the existence of inhibitors....
COVID-19 is a viral disease caused by a new strain of corona virus. Currently, prognosis and risk stratification of COVID-19 patients is done by the disease's clinical presentation. Therefore, identif...
A follow-up study was conducted among conveniently recruited COVID-19 patients attended from March to June 2021. Socio-demographic and clinical data were collected using a structured questionnaire and...
Baseline PT at a cut-off value ≥ 16.25 seconds differentiated severe COVID-19 patients from mild and moderate patients (AUC: 0.89, 95% CI: 0.83-0.95). PT also differentiated mild COVID-19 patients fro...
Prolonged baseline PT was observed in severe COVID-19 patients. Prolonged baseline PT was also predicted to worsen prognosis. An increase from the baseline PT was associated with worsen prognosis. The...
Unfractionated heparin is used to prevent coagulation activation in patients undergoing extracorporeal membrane oxygenation (ECMO) support. We designed this study to determine the preferable indicator...
We conducted a retrospective study and divided the patients into an activated coagulation time (ACT)-target group and an activated partial thromboplastin time (aPTT)-target group. The correlations bet...
Thirty-six patients were included (19 aPTT-target and 17 ACT-target patients); a total of 555 matched pairs of ACT/aPTT results were obtained. The correlation between the ACT and aPTT measurements was...
The correlation between ACT and aPTT and the heparin dose was poor. The aPTT group had fewer daily heparin dose changes and a lower cumulative heparin dose per day than the ACT group, with no more ble...